What's new? Log in Free sign up

Myriad Genetics (MYGN) News and press releases

Company Profile

News

From Benzinga Pro

Insiders Selling DocuSign, Adobe And 2 Other Stocks

News, Short Ideas, Small Cap, Insider Trades, Pre-Market Outlook, Markets, Trading Ideas

The Nasdaq settled higher by 2% on Monday. Investors, meanwhile, focused on some notable insider trades.

Raymond James Upgrades Natera & Myriad Genetics, While Downgrading This Stock

Analyst Color, News, Upgrades, Downgrades, Health Care, Price Target, Small Cap, Analyst Ratings, Movers, Trading Ideas, General

Benzinga's Top Ratings Upgrades, Downgrades For January 18, 2023

Upgrades, Downgrades, Initiation, Intraday Update, Analyst Ratings

Raymond James Upgrades Myriad Genetics to Outperform, Announces $25 Price Target

News, Upgrades, Price Target, Analyst Ratings

Raymond James analyst Andrew Cooper upgrades Myriad Genetics (NASDAQ:MYGN) from Market Perform to Outperform and announces $25 price target.

Stocks That Hit 52-Week Lows On Friday

Friday's session saw 75 companies set new 52-week lows.

Stocks That Hit 52-Week Lows On Tuesday

Tuesday's session saw 325 companies set new 52-week lows.

Reported Late Thursday, Myriad Genetics Patient Outcomes Study Shows RiskScore Leads To More Accurate Breast Cancer Risk Prediction Than Standard-Of-Care Risk Model

Biotech, News, General

Myriad Genetics, Inc. (NASDAQ:MYGN), a leader in genetic testing and precision medicine, today presented results from a longitudinal study validating RiskScore as a well-calibrated and more accurate predictor

Press releases

From Benzinga Pro

Myriad Genetics Highlights 2022 Research Findings that Help Advance More Accessible and Equitable Genetic Testing

Health Care, Analyst Ratings, Press Releases

SALT LAKE CITY, Feb. 07, 2023 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc., (NASDAQ:MYGN), a leader in genetic testing and precision medicine, highlighted impactful clinical studies from 2022 that underscore the company's

Myriad Genetics Applauds New Guidelines Recommending Screening for Chromosomal Abnormalities

Health Care, Press Releases, General

Myriad Genetics continues to advance non-invasive prenatal screening with Prequel® and the forthcoming FirstGene™ test using AMPLIFY™ technology SALT LAKE CITY, Jan. 05, 2023 (GLOBE NEWSWIRE) --

Myriad Genetics Hires Five Senior Leaders to Advance Commercial Growth Plans

New leaders to elevate product portfolio, customer-centric commercial capabilities, and sales and marketing execution SALT LAKE CITY, Dec. 19, 2022 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc., (NASDAQ:MYGN), a leader in

Myriad Genetics Patient Outcomes Study Shows RiskScore Leads to More Accurate Breast Cancer Risk Prediction than Standard-of-Care Risk Model

Health Care, Press Releases

SALT LAKE CITY, Dec. 08, 2022 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc. (NASDAQ:MYGN), a leader in genetic testing and precision medicine, today presented results from a longitudinal study validating RiskScore as a

Myriad Genetics to Present New Data at San Antonio Breast Cancer Symposium Showcasing Advancements in Breast Cancer Risk Assessment and Treatment

News, Press Releases, General

Spotlight discussion highlights how combined risk score may lead to improved breast cancer prevention and screening strategies. SALT LAKE CITY, Nov. 29, 2022 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc., (NASDAQ:MYGN) a

GeneSight Mental Health Monitor Reveals Gap on the Front Line of Mental Health Care

SALT LAKE CITY, Nov. 17, 2022 (GLOBE NEWSWIRE) -- More than 83% of primary care providers (PCPs) wish more of their patients would talk to them about mental health issues and concerns so they can provide better overall